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Introduction: Patients with small-cell lung cancer (SCLC) typi-
cally respond well to initial chemotherapy. However, relapse invari-
ably occurs, and topotecan, the only approved second-line treatment 
option, has limited efficacy. Taxanes have activity in SCLC, and 
cabazitaxel is a second-generation taxane with potential for enhanced 
activity in chemorefractory malignancies.
Methods: Patients with SCLC who relapsed after initial platinum-based 
chemotherapy were randomly assigned to receive cabazitaxel 25 mg/m2 
every 21 days or topotecan 1.5 mg/m2 on days 1–5 every 21 days. Two 
patient subgroups, defined by chemosensitive and chemo-resistant/
refractory disease, were assessed in combination and separately.
Results: The safety profile of cabazitaxel and topotecan was con-
sistent with previous studies, and despite considerable toxicity in 
both arms, no new safety concerns were identified. Patients receiv-
ing cabazitaxel had inferior progression-free survival compared with 
topotecan (1.4 versus 3.0 months, respectively; two-sided p < 0.0001; 
hazard ratio = 2.17, 95% confidence interval = 1.563–3.010), and 
results were similar in both the chemosensitive and chemorefractory 
subgroups. No complete responses were observed in either arm, and 
no partial responses were observed in the cabazitaxel group. The 
partial response rate in the topotecan arm was 10%. Median overall 
survival was 5.2 months in the cabazitaxel arm and 6.8 months in 
the topotecan arm (two-sided p = 0.0125; hazard ratio = 1.57, 95% 
confidence interval = 1.10–2.25).
Conclusion: Cabazitaxel, a next-generation taxane, had inferior 
efficacy when compared with standard-dose topotecan in the treat-
ment of relapsed SCLC. Topotecan remains a suboptimal therapy, 
and continued efforts to develop improved second-line treatments are 
warranted.
Key Words: Cabazitaxel, Phase 2, Small-cell lung cancer, Relapse, 
Topotecan.
(J Thorac Oncol. 2015;10: 1221–1228)
Small-cell lung cancer (SCLC) constitutes 12%–14% of all lung cancers, and is characterized by a rapid doubling 
time, a high growth fraction, and early development of sys-
temic metastases.1,2 While initially quite responsive to chemo-
therapy, resistance invariably develops. As a result, SCLC has 
a poor prognosis, with a median survival without treatment 
of 2 to 4 months.3 With treatment, disease extent is consid-
ered the most reproducible prognostic factor. Two-year sur-
vival rates range from 20% to 40% for limited-stage disease 
(restricted to one lung or local tissues/lymph nodes) and 5% 
or less for extensive-stage disease (metastatic to contralateral 
lung or other sites).1–3
Platinum-based chemotherapy is first-line standard of 
care for SCLC. Etoposide with cisplatin or carboplatin is the 
most commonly used regimen,2–4 although irinotecan plus 
carboplatin is an alternative option.2,5 Despite high response 
rates to first-line chemotherapy, most patients with SCLC 
experience rapid relapse.6 Patients with relapsed SCLC can 
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be categorized into two groups: those who relapse during or 
within 3 months of first-line therapy are considered chemo-
refractory (or resistant), and have a response rate to second-
line chemotherapy of less than or equal to 10%; those who 
relapse after 3 months or more have chemosensitive disease, 
and have a response rate to second-line chemotherapy of 
~25%.2 Although several chemotherapies have demonstrated 
single-agent activity in relapsed SCLC, topotecan is currently 
considered to be the standard treatment.2,7 In phase III trials in 
relapsed SCLC, topotecan treatment resulted in longer overall 
survival (OS) compared with best supportive care (26 versus 
14 weeks)8 and better symptom control versus a cyclophos-
phamide–doxorubicin–vincristine regimen.9 Across several 
studies of patients with relapsed SCLC, median survival time 
has ranged from 14 to 35 weeks.7 Therefore, new second-
line therapies are needed to improve survival in patients with 
relapsed SCLC.
The first-generation taxanes, docetaxel and paclitaxel, 
have shown activity as first- or second-line single-agent treat-
ments in SCLC.10–12 In a phase II study of paclitaxel in patients 
with extensive-disease SCLC, 11 patients (34%) had a par-
tial response (PR) and six patients (19%) had stable disease.10 
In another phase II study of paclitaxel, the overall response 
rate was 53%.12 In a phase II study of docetaxel in previously 
treated patients with SCLC, seven patients (25%) had a PR 
and seven patients (25%) had stable disease.11
Cabazitaxel is a second-generation taxane that has 
demonstrated activity in the second-line treatment of chemo-
therapy-resistant solid tumors.13,14 In particular, in the pivotal 
phase III TROPIC trial in patients with metastatic castration-
resistant prostate cancer progressing after docetaxel therapy, 
cabazitaxel plus prednisone had superior efficacy versus mito-
xantrone plus prednisone, including significantly longer OS 
and progression-free survival (PFS),13 leading to regulatory 
approval worldwide. Interestingly, unlike other taxanes, caba-
zitaxel crosses the blood–brain barrier,15 which could be thera-
peutically beneficial in cancers, such as SCLC where brain 
metastases are common. The paucity of therapeutic options 
and activity of taxanes in SCLC, the ability of cabazitaxel to 
cross the blood–brain barrier, and the activity of cabazitaxel 
in chemorefractory tumors provide a compelling rationale to 
assess cabazitaxel as a treatment for SCLC.
This phase II study evaluated the efficacy of cabazitaxel 
versus topotecan in patients with SCLC that had progressed 
during or after first-line platinum-based chemotherapy.
PATIENTS AND METHODS
Study Population
Eligible patients had histologically/cytologically docu-
mented locally advanced or metastatic SCLC that relapsed 
during or after first-line platinum-based chemotherapy. 
Patients were aged greater than or equal to 18 years, had mea-
surable disease according to Response Evaluation Criteria 
In Solid Tumors (RECIST) 1.116 and an Eastern Cooperative 
Oncology Group performance status less than or equal to one. 
Patients were required to have received no more than one prior 
chemotherapy regimen, and to have adequate hematologic and 
organ function. Exclusion criteria included: prior topotecan 
or taxane treatment; prior chemotherapy, radiotherapy (except 
for bone pain palliation), or surgery within 28 days; treatment 
with any investigational drug within 30 days; uncontrolled 
metastases of the central nervous system; known leptomen-
ingeal metastases; other invasive neoplasm requiring ongoing 
therapy; unresolved adverse event (AE) of grade greater than 
one (except alopecia) resulting from prior anticancer therapy 
(according to National Cancer Institute Common Terminology 
Criteria [NCI CTCAE] v4.03);17 or myocardial infarction, 
severe/unstable angina pectoris, coronary/peripheral artery 
bypass graft, New York Heart Association Class III or IV con-
gestive heart failure, stroke or transient ischemic attack within 
6 months before study enrollment.
The study was conducted according to the Declaration 
of Helsinki with approval from ethics committees at each 
institution. Patients provided written informed consent.
Study Design
This was a phase II, open-label study (ARD12166; 
NCT01500720, ClinicalTrials.gov). Patients were randomly 
assigned (1:1) to receive cabazitaxel or topotecan. Patients 
were divided evenly into two subgroups depending on whether 
their disease had progressed (by RECIST 1.1) either greater 
than or equal to 90 days after completing first-line chemo-
therapy (chemosensitive subgroup) or during or up to 90 
days after completing first-line chemotherapy (chemorefrac-
tory subgroup). Patients were also stratified by the presence 
of brain metastases and serum lactate dehydrogenase (LDH) 
concentration.
The primary endpoint was PFS, defined as time from 
randomization to documented tumor progression or death 
from any cause, whichever came first. Secondary endpoints 
included disease progression-free rate at week 12, response 
rate, duration of response, OS, and safety. Progression and 
response were defined per RECIST 1.1.
Study Treatment
Cabazitaxel 25 mg/m2 was administered as a 1-hour 
intravenous (IV) infusion on day 1 every 21 days. Topotecan 
1.5 mg/m2 was administered as a 30-minute IV infusion on days 
1–5 every 21 days. For cabazitaxel, premedication included an 
antihistamine (dexchlorpheniramine 5 mg, diphenhydramine 
25 mg, or equivalent), a steroid (dexamethasone 8 mg or equiv-
alent) and an H2 antagonist (ranitidine 50 mg or equivalent). 
Premedications were administered by IV infusion at least 30 
minutes before each cabazitaxel dose. If IV antihistamines 
were not available, premedication for hypersensitivity could be 
administered per local practice. Antiemetic prophylaxis with 
ondansetron, granisetron or dolasetron, or per local practice 
for topotecan, was permitted. Supportive care with granulocyte 
colony-stimulating factor (G-CSF) could be considered in both 
treatment arms, in accordance with ASCO guidelines.18
Safety Assessments
The safety population was defined as all randomized 
patients who received at least one dose of cabazitaxel or topote-
can during the treatment period. Patients had a full health evalu-
ation before treatment initiation. On-study safety assessments 
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included: physical examinations, AE monitoring, hematology, 
blood chemistry, coagulation and urine analysis, and 12-lead 
electrocardiograms. AEs and laboratory data were graded using 
NCI CTCAE v4.03.17 Safety assessments were also performed 
within 22–30 days after the final dose of study treatment. In the 
follow-up period, ongoing serious and treatment-related AEs 
and concomitant medications were monitored until recovery 
from the AE or stabilization of the patient’s condition.
Efficacy Assessments
The intent-to-treat population was defined as all random-
ized patients according to treatment arm. Tumors were assessed 
at baseline and every 6 weeks during treatment using abdomi-
nal and chest computerized tomography or magnetic reso-
nance imaging. Brain computerized tomography or magnetic 
resonance imaging was performed every 6 weeks to follow 
metastases found at baseline or if new lesions were suspected. 
If study treatment was discontinued before disease progression, 
tumor assessments continued every 6 weeks until radiological 
progression or study cut-off, whichever came first. For imag-
ing reviews, the same processes and technology (MEDIAN 
Technologies) were used at the investigator sites, and centrally.
Statistical Analysis
PFS, OS, and duration of response in the cabazitaxel and 
topotecan arms were compared using log-rank tests, stratified by 
brain metastases and LDH level. Hazard ratios (HRs) and corre-
sponding 95% confidence intervals (CIs) were estimated using the 
Cox proportional hazard model, stratified using the same factors 
described above. Median PFS and OS and corresponding 95% CIs 
were calculated using Kaplan–Meier estimates. Progression-free 
rate at week 12 and response rate were compared between treat-
ment arms using a χ2 test. A logistic regression model was used for 
additional exploratory analyses. The study sample size was cho-
sen to enable a 30% risk reduction in hazard rate to be detected 
in the primary endpoint for the treatment arm versus the control 
arm, assuming a median PFS of 4.0 months in the control arm 
and 5.7 months in the experimental arm, based on a log-rank test 
with a one-sided 10% significance level. Based on these assump-
tions, 172 eligible patients (86 per arm) and 142 PFS events were 
needed to achieve 80% power for the study.
RESULTS
Patient and Disease Characteristics
Overall, 179 patients were randomized (Supplementary 
Figure S1, Supplemental Digital Content, http://links.lww.
com/JTO/A848). In the total population, 70% were male, 
median age was 61 years, and all but one patient had an 
Eastern Cooperative Oncology Group performance status of 
0 or 1 (Table 1). Approximately half of patients (51%) were 
considered chemosensitive. Most patients (94%) had meta-
static disease at study entry, and the most frequent metastatic 
sites were lung, lymph node, and liver. Brain metastases were 
present in 28% of patients. Median time from initial diagnosis 
to study treatment was 8.6 months. Patient demographics and 
baseline disease characteristics were balanced across treat-
ment groups.
Treatment Exposure
Ninety and 89 patients were randomly assigned to 
receive cabazitaxel or topotecan, of which 89 and 88 patients 
received treatment, respectively. The median number of treat-
ment cycles with cabazitaxel or topotecan, respectively, was 
2.0 versus 4.0 in the overall group, 2.0 versus 3.0 in the che-
morefractory subgroup, and 2.5 versus 4.0 in the chemosen-
sitive subgroup (Supplementary Table S1, SDC, http://links.
lww.com/JTO/A848). Dose delays (study dose given later than 
3 days after the scheduled time in any cycle) were required by 
12 patients (13%) who received cabazitaxel, compared with 45 
patients (51%) who received topotecan. Dose reductions were 
required by 18 patients (20%) who received cabazitaxel, com-
pared with 33 patients (38%) who received topotecan. Among 
treated patients, cabazitaxel or topotecan was discontinued by 
88 patients (99%) and 87 patients (99%), respectively, and the 
most frequent reasons for discontinuation in both arms were 
disease progression (cabazitaxel, 79%; topotecan, 57%) and 
AE (cabazitaxel, 16%; topotecan, 27%).
Survival
Median PFS was 1.4 months in the cabazitaxel arm 
versus 3.0 months in the topotecan arm (HR = 2.17, 95% 
CI = 1.563–3.010; two-sided p < 0.0001). Results were simi-
lar in both the chemosensitive and chemorefractory subgroups 
(Fig. 1). The progression-free rates at week 12 for cabazitaxel 
and topotecan were, respectively, 19% versus 53% in the over-
all group (p < 0.0001), 29% versus 63% in the chemosensitive 
subgroup (p = 0.0011), and 9% versus 42% in the chemore-
fractory subgroup (p = 0.0004).
Median OS in the total population was 5.2 months with 
cabazitaxel versus 6.8 months with topotecan (HR = 1.57, 95% 
CI = 1.10–2.25; two-sided p = 0.0125), and trends were similar 
in the chemosensitive and chemorefractory subgroups (Fig. 2).
Potential heterogeneity of the treatment effect was 
analyzed in a subgroup analysis of PFS and OS. A subgroup 
effect on both PFS and OS trended toward topotecan for most 
factors tested (Fig. 3).
Response
Overall, 152 patients had measurable lesions present 
at baseline and were evaluable for tumor response (73 in the 
cabazitaxel arm, 79 in the topotecan arm). No patient had a 
complete response. No patient receiving cabazitaxel had a PR, 
compared with eight PRs (10%) in the topotecan arm (8% and 
12% in the chemorefractory and chemosensitive subgroups, 
respectively). In the overall population, stable disease was 
recorded as best response in 16 patients (22%), who received 
cabazitaxel (14% and 29% of chemorefractory and chemo-
sensitive patients, respectively) and 50 patients (63%), who 
received topotecan (57% and 69% of chemorefractory and 
chemosensitive patients, respectively; Table 2).
Safety
In the safety population, 80 cabazitaxel-treated patients 
(90%) had a treatment-emergent adverse event (TEAE) of 
any grade, compared with 83 topotecan-treated patients 
(94%). Grade 3/4 TEAEs occurred in 52 patients (58%) in 
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the cabazitaxel arm, and in 63 patients (72%) in the topotecan 
arm. In the cabazitaxel arm, the most frequent nonhemato-
logic TEAEs of any grade were fatigue (29%), diarrhea (19%), 
decreased appetite (18%), and vomiting (18%; Table 3). In 
the topotecan arm, the most frequent nonhematologic TEAEs 
of any grade were dyspnea (25%), fatigue (25%), asthenia 
(20%), and decreased appetite (15%).
The most frequent hematologic AE was febrile neu-
tropenia/neutropenic infection/neutropenic sepsis (cabazi-
taxel 18% versus topotecan 24%). The most frequent grade 
≥ 3 hematologic laboratory abnormalities with cabazitaxel 
were neutropenia (57%), leukopenia (52%), and lympho-
penia (39%), and with topotecan were neutropenia (78%), 
leukopenia (65%), and thrombocytopenia (45%; Table 3). 
G-CSF use was comparable in both treatment arms: ther-
apeutic G-CSF was administered to 25 patients (28%) in 
the cabazitaxel arm and 23 patients (26%) in the topotecan 
arm; prophylactic G-GCF was administered to 53 patients 
(60%) in the cabazitaxel arm and 49 patients (56%) in the 
topotecan arm.
In the cabazitaxel arm, 36 patients (40%) experienced 
a serious TEAE, compared with 41 patients (47%) in the 
topotecan arm. Grade ≥ 3 serious TEAEs occurred in 35 
patients (39%) treated with cabazitaxel, compared with 
39 patients (44%) treated with topotecan. The most fre-
quent serious TEAEs of any grade with cabazitaxel were 
febrile neutropenia/neutropenic infection/neutropenic sep-
sis (13%), and hyponatremia (3%), and with topotecan 
were febrile neutropenia/neutropenic infection/neutropenic 
sepsis (18%), thrombocytopenia (11%), anemia (7%), and 
pneumonia (7%).
During the treatment period (from start of treatment 
until 30 days after the final dose), there were 12 deaths in 
the cabazitaxel arm and 13 deaths in the topotecan arm, of 
which five and seven deaths, respectively, were due to an AE. 
Deaths were considered related to treatment in two patients 
receiving cabazitaxel (both due to neutropenic infection) and 
in four patients receiving topotecan (three with febrile neu-
tropenia/neutropenic infection, and one with cardiopulmo-
nary failure).
TABLE 1.  Patient Demographics and Baseline Disease Characteristics by Treatment Arm in the Overall Population and in 
Chemorefractory and Chemosensitive Subgroups
Overall Population Chemorefractory Subgroup Chemosensitive Subgroup
Cabazitaxel 
(n = 90)
Topotecan 
(n = 89)
Cabazitaxel 
(n = 45)
Topotecan 
(n = 43)
Cabazitaxel 
(n = 45)
Topotecan  
(n = 46)
Median age, years (range) 60 (37–82) 62 (27–80) 58 (37–76) 60 (27–80) 62 (40–82) 65 (33–80)
ECOG PS, n (%)
  ≤1 90 (100) 88 (98.9) 45 (100) 43 (100) 45 (100) 45 (97.8)
  2 0 1 (1.1) 0 0 0 1 (2.2)
Patient subgroup, n (%)
  Chemorefractory 45 (50.0) 43 (48.3) 45 (100) 43 (100) 0 0
  Chemosensitive 45 (50.0) 46 (51.7) 0 0 45 (100) 46 (100)
LDH concentration, n (%)
  ≤ULN 46 (51.1) 46 (51.7) 18 (40.0) 17 (39.5) 28 (62.2) 29 (63.0)
  >ULN 44 (48.9) 43 (48.3) 27 (60.0) 26 (60.5) 17 (37.8) 17 (37.0)
Median time from initial diagnosis to study 
treatment, months (range)a
8.7 (3–56) 8.5 (3–36) 6.8 (3–56) 7.1 (3–17) 10.7 (5–22) 10.5 (5–36)
Extent of disease at study entry, n (%)
  Metastatic 87 (96.7) 81 (91.0) 44 (97.8) 41 (95.3) 43 (95.6) 40 (87.0)
  Locoregional 3 (3.3) 8 (9.0) 1 (2.2) 2 (4.7) 2 (4.4) 6 (13.0)
Number of organs involved at baseline, n (%)
  1–3 46 (51.1) 35 (39.3) 21 (46.7) 13 (30.2) 25 (55.6) 22 (47.8)
  4–5 38 (42.2) 45 (50.6) 19 (42.2) 25 (58.1) 19 (42.2) 20 (43.5)
  6–8 6 (6.7) 9 (10.1) 5 (11.1) 5 (11.6) 1 (2.2) 4 (8.7)
Brain metastases, n (%) 25 (27.8) 25 (28.1) 13 (28.9) 12 (27.9) 12 (26.7) 13 (28.3)
Other most common sites of metastasis, n (%)
  Lung 88 (97.8) 83 (93.3) 44 (97.8) 39 (90.7) 44 (97.8) 44 (95.7)
  Lymph node 76 (84.4) 76 (85.4) 39 (86.7) 39 (90.7) 37 (82.2) 37 (80.4)
  Liver 43 (47.8) 45 (50.6) 24 (53.3) 24 (55.8) 19 (42.2) 21 (45.7)
  Bone 28 (31.1) 34 (38.2) 18 (40.0) 19 (44.2) 10 (22.2) 15 (32.6)
  Adrenal gland 24 (26.7) 26 (29.2) 8 (17.8) 14 (32.6) 16 (35.6) 12 (26.1)
aPatients with available data: total population, cabazitaxel n = 89 and topotecan n = 88; chemosensitive subgroup, cabazitaxel n = 44 and topotecan n = 45.
ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; ULN, upper limit of normal.
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DISCUSSION
In the late 1990s, topotecan replaced the cyclophospha-
mide–doxorubicin–vincristine regimen as standard second-
line treatment for SCLC based on its similar efficacy in patients 
with chemosensitive SCLC (response rate 24%, median OS 
25 weeks) and better symptom control.9 Confirmation that 
topotecan prolonged survival and improved quality of life in 
patients with relapsed SCLC compared with best supportive 
care followed in 2006,8 leading to regulatory approval in this 
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FIGURE 1.  PFS. A, Intent-to-treat population. B, 
Chemorefractory subgroup. C, Chemosensitive subgroup. 
CI, confidence interval; HR, hazard ratio; PFS, progression-
free survival.
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FIGURE 2.  OS. A, Intent-to-treat population. B, 
Chemorefractory subgroup. C, Chemosensitive subgroup. CI, 
confidence interval; HR, hazard ratio; OS, overall survival.
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indication.19 Since then, however, no other single agent or 
combination has shown a significant benefit over topotecan. 
Although amrubicin (an anthracycline) demonstrated supe-
rior activity versus topotecan in a phase II trial in Japanese 
patients, no survival benefit was observed in phase II and III 
trials performed in Western populations.20–22 Results from a 
recent phase III study in Japanese patients suggest that a cis-
platin–etoposide–irinotecan regimen is superior to topotecan 
in relapsed SCLC that is sensitive to first-line treatment, and 
this regimen has the potential to become standard second-line 
chemotherapy. However, increased toxicity was noted in the 
combination arm. To date, these data have been presented only 
in abstract form, and full publication is awaited.23
First-generation taxanes have shown modest activity in 
the treatment of relapsed SCLC. In phase II studies of pacli-
taxel administered alone or in combination with other agents 
in patients with previously treated SCLC, overall response 
rates have ranged from 24–73%.24–27 Similarly, docetaxel treat-
ment in the second-line setting resulted in an overall response 
rate of 25%,11 although in a trial in patients with limited or 
extensive-stage disease, a docetaxel/gemcitabine combination 
was reported to be inactive.28 However, no taxane-based regi-
men has emerged as being significantly more effective than 
established treatments.19 Cabazitaxel is a second-generation 
taxane developed to overcome resistance to first-generation 
taxanes,29 and has shown comparable antitumor activity to 
FIGURE 3.  Subgroup analysis of PFS and OS in patients treated with cabazitaxel or topotecan. Overall Cox model was strati-
fied for brain metastases and lactate dehydrogenase (LDH) level, as specified at randomization. Cox models for subgroups were 
not stratified. CI, confidence interval; ITT, intent-to-treat; ULN, upper limit of normal; PFS, progression-free survival; OS, overall 
survival; cbz, cabazitaxel; top, topotecan.
TABLE 2.  Objective Tumor Response Rates in the Overall Tumor-Evaluable Population and in Chemorefractory/Chemosensitive 
Subgroups
Response, n (%)
Overall Population Chemorefractory Subgroup Chemosensitive Subgroup
Cabazitaxel 
(n = 73)
Topotecan 
(n = 79)
Cabazitaxel 
(n = 35)
Topotecan 
(n = 37)
Cabazitaxel 
(n = 38)
Topotecan 
(n = 42)
Complete response 0 0 0 0 0 0
Partial response 0 8 (10.1) 0 3 (8.1) 0 5 (11.9)
Stable disease 16 (21.9) 50 (63.3) 5 (14.3) 21 (56.8) 11 (28.9) 29 (69.0)
Disease progression 51 (69.9) 18 (22.8) 28 (80.0) 11 (29.7) 23 (60.5) 7 (16.7)
Not evaluable/missing data 6 (8.2) 3 (3.8) 2 (5.7) 2 (5.4) 4 (10.5) 1 (2.4)
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docetaxel in docetaxel-sensitive tumor models and increased 
potency versus docetaxel in taxane-resistant tumor models.30
In this study, cabazitaxel failed to demonstrate improved 
efficacy versus topotecan in patients with SCLC that had pro-
gressed during or after first-line platinum-based chemotherapy. 
In fact, cabazitaxel treatment resulted in a significantly shorter 
PFS and shorter OS than topotecan. Median OS seen with 
topotecan in this study (7.2 months) is similar to that reported 
in previous studies.8,9 Patient and disease characteristics were 
well balanced between treatment arms. Furthermore, analysis 
of PFS and OS in patient subgroups, defined by LDH level, 
presence of brain metastasis, age, global region, stage at diag-
nosis or number of organs involved, consistently favored topo-
tecan treatment over cabazitaxel, suggesting no heterogeneity 
of treatment effect. Objective response rates and progression-
free rate at week 12 also favored the topotecan arm. It is cur-
rently unclear why cabazitaxel treatment resulted in a lower 
overall response rate compared with single-agent treatment 
with first generation taxanes in SCLC.10–12,27
In previous studies, frequent cabazitaxel-associated 
AEs have included hematologic events, such as anemia, leu-
copenia, and neutropenia, in addition to gastrointestinal dis-
turbances and fatigue.13,14,31–33 The safety profile of cabazitaxel 
in this study was consistent with previous studies and no 
new safety concerns were identified. However, in this study, 
the toxicity of both treatments was considerable. The rate of 
febrile neutropenia/neutropenic infection/neutropenic sepsis 
was 18% and 24% in the cabazitaxel and topotecan arms, 
respectively, despite 60% and 56% receiving prophylactic 
G-CSF. Dose delays and reductions were also common in both 
arms. Despite the observed survival benefit, treatment with 
the “traditional” topotecan regimen resulted in four treatment-
related deaths, which is certainly a concern for a palliative 
treatment where the survival benefit is modest.
Overall, this randomized, phase II study suggests that 
cabazitaxel 25 mg/m2 administered every 3 weeks, although 
relatively well tolerated in patients with relapsed SCLC, had 
inferior efficacy compared with topotecan 1.5 mg/m2 admin-
istered on days 1–5 every 3 weeks. Results do not justify 
further investigation of cabazitaxel treatment in this disease. 
While it is clear that cabazitaxel is an inferior second-line treat-
ment in patients with SCLC, topotecan remains a suboptimal 
therapy, and efforts to improve treatment in this setting remain 
warranted.
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